Compare SKY & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | LEGN |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.2B |
| IPO Year | 1994 | 2020 |
| Metric | SKY | LEGN |
|---|---|---|
| Price | $91.83 | $23.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $101.83 | $45.62 |
| AVG Volume (30 Days) | 680.3K | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.02 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $2,663,639,000.00 | N/A |
| Revenue This Year | $4.80 | $39.73 |
| Revenue Next Year | $7.49 | $23.42 |
| P/E Ratio | $51.70 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $63.87 | $16.24 |
| 52 Week High | $99.17 | $37.50 |
| Indicator | SKY | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 67.14 |
| Support Level | $89.31 | $22.40 |
| Resistance Level | $97.54 | $23.65 |
| Average True Range (ATR) | 3.44 | 1.19 |
| MACD | 1.89 | 0.33 |
| Stochastic Oscillator | 76.29 | 89.43 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several locations across the US. The Company has two reportable segment U.S. Factory-built Housing and Canadian Factory-built Housing. The majority of the revenue is generated from U.S. Factory-built Housing.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.